Foundational guide
NAD+ Side Effects: Mechanism, Data, and the Gaps
The sensations reported during an infusion may be about the rate of administration rather than about the molecule, and nothing separates the two.
NAD+ side effects are usually described as a scene rather than a dataset: a flush, a tightness in the chest, nausea partway through an infusion, and staff slowing the drip until it passes. That account is consistent enough across clinics and clients to be treated as real.
What it demonstrates is less obvious than it looks, and it is the natural entry point into a safety record assembled from three sources that do not overlap with one another.
Supplier publishing lot-level data
NAD+, Ascension Peptides
Every lot carries certificates from two independent laboratories. The code below halves the listed price on the vial.
Quoted per 100 mg because NAD+ is dosed in hundreds of milligrams, not the single milligrams a peptide vial holds. Buying 3, 5 or 10 takes 3%, 5% or 10% off the list price. Free shipping starts at $250.
- Kovera Labs and MZ Biolabs certificates per lot
- Carriage free above $250
- Dispatched same day before 2pm CST
Supplied for laboratory research use and not for human consumption. Affiliate links: a commission may be earned at no cost to the reader, and it does not affect the assessment above. Prices verified August 20, 2026.
NAD+ side effects: three records, two of them about something else
The first record is oral precursor trials. Nicotinamide riboside and nicotinamide mononucleotide have been given to human participants in controlled studies where adverse events were collected systematically. That is a real safety dataset in humans, and it belongs to a swallowed precursor.
The second is clinic experience with infused NAD+. It covers the right intervention and the right route, and it is uncontrolled, unstandardised and unpublished, gathered by the parties supplying the service.
The third record would be controlled human trials of injected NAD+ with prespecified safety endpoints. That record is essentially absent, and its absence is why the first two get pressed into service to cover a question neither was built to answer.
Effects tied to the rate of administration, not the molecule
The infusion sensations are worth examining closely, because they illustrate a distinction that vendor pages and critics both tend to skip.
An effect that appears during administration, intensifies when the drip runs faster, subsides when it is slowed and disappears when it stops has a profile consistent with the rate at which something is being delivered rather than with the compound’s pharmacology as such. Many intravenous substances behave this way, including entirely unremarkable ones, and the pattern says as much about how a bolus is handled as about what is in it.
Distinguishing rate related effects from compound related effects is not a matter of judgement. It requires varying the rate systematically, holding everything else constant, and comparing against a control infusion. Nobody administering these products commercially has an incentive to run that comparison, and it has not appeared in the published literature.
What a controlled precursor trial does and does not detect
Oral precursor trials collected adverse events on a schedule, with definitions agreed in advance, against a comparison group. That design detects common events reliably, because if a symptom occurs often it will appear at a different rate in the two arms.
It has structural limits. A trial enrols a defined population, usually healthier than the general public, so events specific to people who were excluded do not appear. It runs for a fixed period, so anything with a longer latency falls outside the observation window. And it enrols a limited number of people, so a rare event may not occur at all, which is not evidence that it cannot.
Those limits apply to the precursor. Applied to the injected coenzyme they compound with a prior problem: the trials were not studying it. A reassuring tolerability record for a capsule is not transferable to an intravenous product, because the two differ in the molecule administered, the concentration reached, the speed at which it is reached, and the fact that one bypasses every barrier the other must cross.
The sterility axis an injectable adds
An oral supplement that is contaminated causes gastrointestinal problems. An injected preparation that is contaminated introduces material directly into the bloodstream, and the relevant hazards change category.
Sterility, endotoxin content, particulate matter, correct concentration and the integrity of the container over its shelf life are all properties of a specific batch of a specific preparation. They are unrelated to NAD+ biology and they would apply identically to a sterile bag of anything. For products supplied outside a regulated manufacturing chain, they are also unverifiable by the person receiving them.
This axis is routinely omitted from safety discussion because it is not about the compound. For an injectable it is frequently the more tractable risk, and it is the one a certificate of analysis on a research chemical vial is least equipped to address.
Where the biochemistry suggests something worth measuring
Mechanism does not establish harm, but it does indicate what a safety programme would examine first.
NAD+ is a substrate for sirtuins, for poly ADP ribose polymerases and for CD38, and it participates in signalling through purinergic pathways once degraded extracellularly. Systematically raising the availability of a substrate that several regulated enzyme families draw on is a change to a controlled system, and control systems respond to being pushed. What that response is in humans, over what period, and whether it persists after administration stops are open questions rather than answered ones.
Naming them is not an allegation. It is a statement about which measurements would populate an empty column, and the column is empty. Mechanistic plausibility cuts in both directions here and settles neither, which is exactly why the measurements would be worth having.
| Source of knowledge | Intervention it covers | Organism | Detects well | Misses |
|---|---|---|---|---|
| Controlled oral precursor trials | NR or NMN by mouth | Human | Common short term events | Rare events, long latency, other routes |
| Rodent and cell culture studies | Precursors and direct addition | Mouse, rat, cultured cells | Mechanistic and tissue level changes | Anything species specific to humans |
| Infusion clinic observation | Injected NAD+ | Human clients | Acute events during administration | Delayed effects, anything after the client leaves |
| Client testimonials | Injected NAD+ | Human | Nothing reliably | Everything not volunteered |
| Controlled trials of injected NAD+ | The product sold | Human | Would detect the above | Does not substantially exist |
What approval would have added, and has not
For most medicines the safety information a reader relies on was not produced by a single trial. It was assembled by a regulator, which required a toxicology package before humans were exposed at all, reviewed the trial safety data rather than the sponsor’s summary of it, wrote the contraindications and warnings, and then continued collecting reports after marketing began.
Injected NAD+ has been through none of that. There is no assessed label, so there is no authoritative statement of who should not receive it, what it interacts with, or what to watch for. Absence of a warning here does not mean a hazard was considered and dismissed. It means no institution was ever asked the question.
That distinction matters more for this compound than for most, because the endogenous framing invites people to treat the empty label as reassurance. An empty label and a clean label look identical from the outside and mean opposite things.
Why an absence of reports is not a finding
The internet contains few accounts of serious harm from NAD+ infusions, and that is regularly offered as reassurance. It is not information about the molecule.
Reporting a delayed adverse event requires attributing it to an infusion received weeks earlier, knowing where to report it, and having somewhere that collects such reports. Outside a regulated pathway, no such collection system exists. Nobody is counting, so the count is zero, and a zero produced by the absence of a counter is not a rate. A rate needs a denominator, and the denominator here is not merely uncertain but entirely unrecorded.
Frequently asked questions
- Are NAD+ side effects documented in humans?
- Adverse events are documented for oral precursors in controlled trials. For injected NAD+, what exists is provider observation during administration, which is not a systematic safety record and has not been published in a form a reader can assess.
- Is the flushing during an infusion dangerous?
- That question cannot be answered from the available information. It is described consistently and appears to track the rate of administration, but nothing published characterises what produces it, how often it occurs across providers, or whether anything follows from it.
- Does the compound being made by the body mean it is well tolerated?
- No. Endogenous status describes origin. Every risk here concerns a quantity delivered by a route the body does not use, at a rate it does not produce, to a system that regulates its own supply, plus whatever else is in the container.
- Do the oral precursor safety data cover the infusion?
- They cover a different molecule taken by a different route. Extending them to an infusion assumes equivalence between the two, and that assumption is the thing that has not been tested.
- What would a real safety assessment of the injected form start with?
- Human pharmacokinetics for the infused molecule, then controlled comparison against placebo infusion with adverse events defined and graded in advance, then observation extending well beyond the administration period. None of those three steps has been completed in the published literature.
Limitations of the evidence
This page describes a safety record assembled from sources that do not overlap, and it is not a safety assessment of any product. The systematic human adverse event data described belongs to oral precursors, chiefly nicotinamide riboside and nicotinamide mononucleotide, and does not transfer to an injected preparation that differs in molecule, concentration, rate and route. Provider observation during an infusion is uncontrolled, unstandardised and unpublished. Controlled human trials of injected NAD+ with prespecified safety endpoints are essentially absent, so no rate of any event can be stated, and no absence of reports should be read as an absence of events where nothing collects them. Whether the sensations described during infusion are compound related or rate related has not been tested. Injected or infused NAD+ holds no marketing authorisation in any market, so no assessed label, contraindication list or warning exists, and nothing here describes or recommends human use.